On April 15, 2026 Nucleai, a leader in AI-powered spatial biology analytics, and Sirona Dx, a Technical CRO, specialized in spatial biology and single-cell services, reported a strategic partnership to deliver a fully integrated and scalable spatial proteomics solution for pharmaceutical and biotechnology companies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Spatial proteomics platforms are generating increasingly rich and complex tissue data, yet a significant portion of that data’s biological value remains unrealized. Critical insights, including novel spatial biomarkers, treatment response signatures, and patient stratification patterns, are often under extracted due to sub-optimal assay development and fragmentation across assay development, imaging, and analytics. As multiplex imaging technologies advance, the gap between data generation and actionable insight continues to widen, leaving substantial value unrealized.

This partnership introduces a premium, fully integrated offering for pharma sponsors, delivered as a single engagement unified across the entire workflow. Sirona Dx leads assay design, development, and validation to ensure high-quality image generation, while Nucleai delivers AI-powered spatial analytics from feature extraction through biomarker discovery and biological interpretation. Together, the companies provide a seamless end-to-end solution in which highest quality tissue data is connected directly to actionable biological insight.

"Until now, pharma teams haven’t had a seamless way to translate spatial proteomics data into actionable biological insight," said Avi Veidman, CEO of Nucleai. "Together with Sirona Dx, we’re delivering a single, integrated path from tissue data to meaningful biological insight — enabling more confident biomarker decisions and ultimately improving the probability of clinical success."

"Pharma sponsors are investing heavily in spatial biology and need solutions that match both the quality and complexity of their data," said Nasry Yassa, CEO of Sirona Dx. "Our partnership with Nucleai augments our capabilities to deliver fully integrated insight, providing a more seamless and effective model for supporting drug development programs."

The joint offering supports applications across oncology, immunology, and neuroscience, including biomarker discovery and validation, patient stratification, mechanism of action studies, and clinical trial biomarker programs.

The partnership, combining best-in-class experimental and analytical capabilities, is timed perfectly to meet growing demand from pharma sponsors for integrated spatial biology solutions.

(Press release, Nucleai, APR 15, 2026, View Source [SID1234664414])

On April 15, 2026 Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, reported the pricing of its concurrent public offerings of 10,563,381 shares of common stock, at a public offering price of $142.00 per share, for aggregate gross proceeds of approximately $1.5 billion, and $500.0 million aggregate principal amount of 0.50% convertible senior notes due 2033 (the "notes"). The offering size of the common stock offering was increased from the previously announced offering size of $750.0 million and the offering size of the note offering was increased from the previously announced offering size of $250.0 million. The issuance and sale of the common stock and the notes are scheduled to settle on April 16, 2026 and April 17, 2026, respectively, subject to customary closing conditions. Revolution Medicines also granted the underwriters of the common stock offering a 30-day option to purchase up to an additional 1,584,506 shares of common stock. The completion of the common stock offering will not be contingent on the completion of the note offering, and the completion of the note offering will not be contingent on the completion of the common stock offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan, TD Cowen and Guggenheim Securities are acting as book-running managers for the note offering and the common stock offering. LifeSci Capital is acting as lead manager for the note offering and the common stock offering.

The notes will be senior, unsecured obligations of Revolution Medicines and will accrue interest at a rate of 0.50% per annum, payable semi-annually in arrears on May 1 and November 1 of each year, beginning on November 1, 2026. The notes will mature on May 1, 2033, unless earlier repurchased, redeemed or converted. Before February 1, 2033, noteholders will have the right to convert their notes only upon the occurrence of certain events. From, and including, February 1, 2033, noteholders may convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Revolution Medicines will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Revolution Medicines’ election. The initial conversion rate is 5.0302 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $198.80 per share of common stock. The initial conversion price represents a premium of approximately 40.0% over the public offering price per share of common stock in the common stock offering. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Revolution Medicines’ option at any time, and from time to time, on or after May 6, 2030 and on or before the 31st scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Revolution Medicines’ common stock exceeds 130% of the conversion price for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

If a "fundamental change" (as defined in the indenture for the notes) occurs, then, subject to a limited exception, noteholders may require Revolution Medicines to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.

Revolution Medicines estimates that the net proceeds from the common stock offering will be approximately $1,435.0 million (or approximately $1,650.4 million if the underwriters of the common stock offering fully exercise their option to purchase additional shares of common stock), after deducting the underwriting discounts and commissions and estimated offering expenses. Revolution Medicines estimates that the net proceeds from the note offering will be approximately $486.8 million, after deducting the underwriting discounts and commissions and estimated offering expenses. Revolution Medicines intends to use the net proceeds from the offerings for general corporate purposes, including research and development expenses, expenses relating to the potential commercialization of one or more of its product candidates, general and administrative expenses and capital expenditures.

The offerings are being made pursuant to an effective shelf registration statement on file with the Securities and Exchange Commission (the "SEC"). Each offering will be made only by means of a prospectus supplement relating to that offering and an accompanying prospectus. An electronic copy of the preliminary prospectus supplement (and, when available, the final prospectus supplement) for each offering, together with the accompanying prospectus, is or will be available on the SEC’s website at www.sec.gov. Alternatively, copies of these documents can be obtained by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected] and [email protected]; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected]; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected].

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities referred to in this press release, nor will there be any sale of any such securities, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

(Press release, Revolution Medicines, APR 15, 2026, View Source [SID1234664363])

On April 15, 2026 Alloy Therapeutics, Inc. ("Alloy"), a biotechnology ecosystem company powering the future of drug discovery and development through AI-driven platforms and integrated services, reported a $40 million Series E financing round, marking a significant step in the company’s evolution from antibody discovery pioneer to full-stack biotech infrastructure company. This latest round of financing values Alloy at $1 billion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Since its founding in 2017, Alloy has collaborated with more than 200 partners across multiple biologic modalities – including antibodies, bispecifics, genetic medicines, and cell therapies – resulting in over 100 licensed therapeutic programs, 22 of which have advanced to clinical development, including two drugs already in Phase 3. Building on its drug discovery foundation, Alloy has expanded its capabilities across the full drug development lifecycle to include pharmacology, preclinical and clinical development services, and biologics manufacturing.

"Alloy is building the infrastructure layer connecting discovery, development, and data across the global biopharma industry. We are bridging the enormous strengths of traditional BioPharma and cutting-edge TechBio to reimagine what’s possible for making new medicine," said Errik Anderson, Founder and CEO of Alloy Therapeutics. "Technological innovation, including AI at every step of the process, is driving a rapid evolution that no single pharma company can keep up with. Alloy’s collaborative, service-oriented model allows our partners to stay at the cutting edge without having to innovate in every dimension or hire the people and infrastructure they may only need intermittently."

Alloy will use the proceeds to accelerate growth across three priorities: deepening its core discovery service in antibodies, genetic medicines, and cell therapies; expanding its downstream preclinical and clinical development services; and accelerating its AI/ML and data layer that connects it all. The future of drug development belongs to capital-efficient builders: virtual biotechs and lean development teams that need world-class infrastructure without owning it. Alloy is that platform: connecting proprietary AI, real-world data, and wet lab execution through on-demand services that federate and protect partner data at every step.

Major investors in the Series E included 8VC, JIC Venture Growth Investments, Echo Capital and multiple family offices who joined Alloy’s existing investors Mubadala Capital, Presight Capital, Thiel Capital, Founders Fund, Alexandria Venture Investments, Gaingels, and Ulysses Diversified Holdings.

"We’ve watched Errik build Alloy methodically for nearly a decade into a company that has quietly redefined what drug development can look like at scale," said Alex Kolicich at 8VC. "While all industries are being disrupted by AI in front of our eyes, Alloy understands that real disruption in biopharma is coming from integrating AI as part of an ‘x-in-the-loop’ strategy with real-world capabilities."

The company continues to expand its footprint through centers of excellence across the U.S., Japan, the Middle East, and emerging innovation markets – building its distributed, locally-executed model for the next era of decentralized drug development.

"Strengthening Japan’s position in global life sciences requires investing in the infrastructure that enables innovation to move faster, more efficiently, and without borders," said Hanae Suzuki, who leads life science investments at JIC Venture Growth Investments. "Alloy’s model – connecting world-class proprietary technologies and services across geographies, including its growing presence in Japan – not only enhances Japan’s integration into the global innovation ecosystem, but also supports the development of globally competitive talent, reflecting exactly the kind of global ecosystem we seek to support."

(Press release, Alloy Therapeutics, APR 15, 2026, View Source [SID1234664399])

On April 15, 2026 Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OPN-6602, a dual EP300/CBP inhibitor, for the treatment of multiple myeloma (MM). The Fast Track designation applies to patients with relapsed/refractory MM who have received at least four prior lines of therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OPN-6602 is an oral, small molecule inhibitor of EP300 and CREB-binding protein (CBP) currently in a Phase 1 clinical trial evaluating safety, tolerability, pharmacokinetics and preliminary clinical activity in patients with relapsed and/or refractory MM.

Multiple myeloma is a hematologic malignancy marked by the uncontrolled proliferation of plasma cells in the bone marrow, often leading to bone damage, kidney dysfunction and immune suppression. Despite therapeutic advances, most patients ultimately relapse or become refractory to available therapies, highlighting an unmet need for novel treatment options.

"Opna Bio has been a pioneer in the EP300/CBP inhibitor space and OPN-6602 was selected for its potency, selectivity, and optimized pharmacokinetic properties. We are encouraged by the progress of the study to date and look forward to reporting emerging clinical data at an upcoming scientific congress," said Reinaldo Diaz, chief executive officer of Opna Bio.

The FDA’s Fast Track designation is designed to facilitate development and expedite review of therapies addressing serious conditions with unmet need. It offers benefits including more frequent FDA interactions, potential eligibility for accelerated approval and priority review, and rolling NDA submission. OPN-6602 was previously granted Orphan Drug Designation by the FDA in January 2025.

(Press release, Opna Bio, APR 15, 2026, View Source [SID1234664415])

On April 14, 2026 Allogene Therapeutics, Inc. (Nasdaq: ALLO) reported the pricing of an underwritten public offering of 87,500,000 shares of its common stock at a price to the public of $2.00 per share. The gross proceeds from this offering are expected to be $175 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions. In addition, Allogene has granted the underwriters for the offering a 30-day option to purchase up to 13,125,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Allogene expects to use the net proceeds from this offering for general corporate purposes, which may include clinical trial expenses, research and development expenses, general and administrative expenses, and capital expenditures.

Goldman Sachs & Co. LLC, Jefferies and TD Cowen are acting as joint bookrunners for the offering. Piper Sandler and William Blair are also acting as joint bookrunners for the offering. Baird and Canaccord Genuity are acting as lead managers for the offering. TPG Capital BD, LLC is acting as co-manager for the offering.

The shares of common stock described above are being offered by Allogene pursuant to a shelf registration statement filed by Allogene with the Securities and Exchange Commission (SEC) that was declared effective on April 25, 2024. A final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at View Source Copies of the final prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at [email protected]; or from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, or by telephone at (877) 821-7388, or by emailing [email protected]; or from TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

(Press release, Allogene, APR 15, 2026, View Source [SID1234664364])